Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Go back to Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 57.29 +1.76 (3.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.53 | 52 Week High | $17.00 | |||
| Open | $56.16 | 52 Week Low | $3.55 | |||
| Day High | $57.42 | P/E | N/A | |||
| Day Low | $55.80 | EPS | $-1.33 | |||
| Volume | 1,136,579 | |||||
